 Safety pharmacokinetics hydroxynaphthoquinone anti-Pneumocystis carinii activity phase human immunodeficiency virus HIV men hydroxynaphthoquinone compound effective prevention treatment murine Pneumocystis carinii pneumonitis phase cohorts human immunodeficiency virus-infected men mg compound daily days sixth cohort mg times days days Evaluation clinical hematologic biochemical studies pharmacokinetics drug-related adverse effect maculopapular rash patient discontinuation drug dosage mg following pharmacokinetic measures maximum plasma concentration micrograms/ml time plasma concentration area plasma concentration-time curve steady state h.micrograms/ml half-life total plasma clearance l/h Compound offers new drug class carinii pneumonia